Physician profile
Jay B Han
NPI 1669468757
$6,574.32
in general payments reported to CMS, 2019-2025
27 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $254 · 2021: $412 · 2022: $853 · 2023: $836 · 2024: $1,257 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,404.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $841.04 | 2019-2025 | |
| Boston Scientific Corporation | $592.11 | 2019-2023 | Bodyguardian, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $557.21 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $465.56 | 2019-2023 | Eliquis, Camzyos |
| Biotronik INC. | $463.60 | 2019-2023 | Acticor 7 Vr-T Dx |
| Amgen INC. | $432.30 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.81 | 2019-2025 | Jardiance |
| Medtronic, INC. | $412.58 | 2022-2025 | Valiant Captivia, Linq II |
| Sanofi-Aventis U.S. LLC | $363.39 | 2019-2023 | |
| Abiomed | $329.33 | 2025 | |
| Shockwave Medical, INC | $295.94 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $256.32 | 2019-2025 | Lifevest |
| Abbott Laboratories | $211.18 | 2021-2024 | Mitraclip |
| Janssen Pharmaceuticals, INC | $156.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $143.41 | 2021-2024 | Verquvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $122.14 | 2019 | |
| Kestra Medical Technology Services, INC. | $118.08 | 2023-2025 | Assure Wcd |
| Angiodynamics, INC. | $84.10 | 2025 | Angiovac |
| Amarin Pharma, INC. | $71.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $58.97 | 2022-2024 | Farxiga, Wainua |
| Baxter Healthcare | $44.74 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $34.93 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $33.20 | 2025 | Evkeeza |
| Scpharmaceuticals INC. | $25.54 | 2025 | |
| Atricure, INC. | $20.95 | 2023 | |
| Bardy Diagnostics, INC. | $13.67 | 2022 | |
| Edwards Lifesciences Corporation | $13.02 | 2023 | Pascal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.